Nature, Published online: 26 March 2025; doi:10.1038/s41586-025-08758-wSTING agonist-based endoplasmic reticulum-targeting molecules can be conjugated directly onto antigens to deliver them to the cross-presentation pathway, improving CD8+ T cell responses against tumours and viruses.